Baker Avenue Asset Management, LP Cue Biopharma, Inc. Transaction History
Baker Avenue Asset Management, LP
- $2.86 Billion
- Q1 2024
A detailed history of Baker Avenue Asset Management, LP transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 32,378 shares of CUE stock, worth $34,968. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,378
Previous 32,378
-0.0%
Holding current value
$34,968
Previous $85,000
28.24%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CUE
# of Institutions
78Shares Held
16.3MCall Options Held
12.9KPut Options Held
39.1K-
Bleichroeder LP New York, NY2.76MShares$2.98 Million1.61% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$2.59 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$2.47 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.24MShares$2.42 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA839KShares$905,6130.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $38.2M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...